SCHEMBL1752479

SCHEMBL1752479

NC(=O)c1cccc(-c2noc(-c3ccccc3F)n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 15/20 1.00
RAB9A P51151 15/20 1.00
MAOA P21397 1/20 0.79
BLVRB P30043 1/20 0.79
HDAC6 Q9UBN7 1/20 0.79
KMT2A Q03164 6/20 0.63
SMN1; SMN2 Q16637 5/20 0.63
MEN1 O00255 5/20 0.63
NFKB1 P19838 3/20 0.63
NFKB2 Q00653 3/20 0.63
RELA Q04206 3/20 0.63
L3MBTL1 Q9Y468 3/20 0.63
PKM P14618 2/20 0.63
MAPK1 P28482 2/20 0.63
GAA P10253 1/20 0.53
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.51
NR1H4 Q96RI1 1/20 0.51
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29842481 1.00 NPC1 (1.00) NPC1RAB9AMAOABLVRBHDAC6
Ataluren SCHEMBL29361641 0.88 MAOA (1.00) NPC1RAB9AMAOABLVRBHDAC6
Ataluren SCHEMBL60614 0.88 MAOA (1.00) NPC1RAB9AMAOABLVRBHDAC6
Ataluren SCHEMBL29360108 0.88 MAOA (1.00) NPC1RAB9AMAOABLVRBHDAC6
Ataluren SCHEMBL29365205 0.88 MAOA (1.00) NPC1RAB9AMAOABLVRBHDAC6
Ataluren SCHEMBL59167 0.87 MAOA (0.97) NPC1RAB9AMAOABLVRBHDAC6
SCHEMBL1752210 0.87 MAOA (0.79) NPC1RAB9AMAOABLVRBHDAC6
Ataluren SCHEMBL59165 0.87 MAOA (0.97) NPC1RAB9AMAOABLVRBHDAC6
SCHEMBL17946207 0.87 MAOA (0.79) NPC1RAB9AMAOABLVRBHDAC6
SCHEMBL12171232 0.87 NPC1 (0.77) NPC1RAB9AMAOABLVRBHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115141120-A Electrooxidation preparation method of astallurens 湖南大学 2022-10-04 CN disclosed
US-9273076-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9273076-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9273076-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20140235586-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2014-08-21 US disclosed
US-20140235586-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2014-08-21 US disclosed
US-20140235586-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2014-08-21 US disclosed
US-8710031-B2 Compounds for nonsense suppression and methods for their use PTC THERAPEUTICS, INC. (US) 2014-04-29 US disclosed
US-8710031-B2 Compounds for nonsense suppression and methods for their use PTC THERAPEUTICS, INC. (US) 2014-04-29 US disclosed
US-8710031-B2 Compounds for nonsense suppression and methods for their use PTC THERAPEUTICS, INC. (US) 2014-04-29 US disclosed
US-20110160164-A1 COMPOUNDS FOR NONSENSE SUPPRESSION AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC (US) 2011-06-30 US disclosed
US-20110160164-A1 COMPOUNDS FOR NONSENSE SUPPRESSION AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC (US) 2011-06-30 US disclosed
US-7902235-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2011-03-08 US disclosed
US-7902235-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2011-03-08 US disclosed
US-7902235-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2011-03-08 US disclosed
US-20090203752-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2009-08-13 US disclosed
US-20090203752-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2009-08-13 US disclosed
US-20090203752-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2009-08-13 US disclosed
EP-1799659-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2007-06-27 EP disclosed
WO-2006044682-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235586-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 NPC1 732/4885RAB9A 2618/4885MAOA 3716/4885
US-20090203752-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 NPC1 732/4885RAB9A 2618/4885MAOA 3716/4885
US-20110160164-A1 COMPOUNDS FOR NONSENSE SUPPRESSION AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 NPC1 786/4885RAB9A 2707/4885MAOA 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.